{"id":609,"date":"2023-11-08T11:06:18","date_gmt":"2023-11-08T02:06:18","guid":{"rendered":"https:\/\/cichlid.tech\/?post_type=contents&#038;p=609"},"modified":"2023-11-11T11:06:35","modified_gmt":"2023-11-11T02:06:35","slug":"gencurix-gets-fda-ok-for-breast-cancer-prognosis-analysis-device","status":"publish","type":"contents","link":"https:\/\/cichlid.tech\/en\/contents\/gencurix-gets-fda-ok-for-breast-cancer-prognosis-analysis-device\/","title":{"rendered":"Gencurix gets FDA OK for breast cancer prognosis analysis device"},"content":{"rendered":"<blockquote><p>The company plans to develop its subsidiary GenoBio&#8217;s GenoCTC v5 as a versatile device for cancer across all stages\n<\/p><\/blockquote>\n<p>South Korean biotech company Gencurix Inc. announced on Wednesday its subsidiary GenoBio has received approval from the US Food and Drug Administration (FDA) for the &#8220;GenoCTC v5,&#8221; a circulating tumor cells (CTCs)-based breast cancer prognosis analysis device.<\/p>\n<p>According to Gencurix, CTCs are tumor cells found in the blood, which are used for monitoring cancer treatment effectiveness and as markers for cancer metastasis.<\/p>\n<p>GenoBio had previously presented research results at the San Antonio Breast Cancer Symposium in December last year, predicting the prognosis of breast cancer patients using this device.<\/p>\n","protected":false},"featured_media":0,"parent":0,"menu_order":0,"template":"","contents-tax":[10],"acf":[],"_links":{"self":[{"href":"https:\/\/cichlid.tech\/en\/wp-json\/wp\/v2\/contents\/609"}],"collection":[{"href":"https:\/\/cichlid.tech\/en\/wp-json\/wp\/v2\/contents"}],"about":[{"href":"https:\/\/cichlid.tech\/en\/wp-json\/wp\/v2\/types\/contents"}],"wp:attachment":[{"href":"https:\/\/cichlid.tech\/en\/wp-json\/wp\/v2\/media?parent=609"}],"wp:term":[{"taxonomy":"contents-tax","embeddable":true,"href":"https:\/\/cichlid.tech\/en\/wp-json\/wp\/v2\/contents-tax?post=609"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}